Preclinical CRO Service for Next Generation Probiotic Research based on Roseburia hominis

R. hominis for Disease Therapeutical Research

Ulcerative Colitis (UC)

Scientists have investigated the mechanisms of R. hominis-host cross talk using both murine and in vitro models. In R. hominis, host intestinal colonization upregulated genes involved in conjugation/mobilization, metabolism, motility, and chemotaxis. In host cells, bacterial colonization upregulated genes associated with antimicrobial peptides, intestinal barrier function, toll-like receptor (TLR) signaling, and T-cell biology. Treatment with the R. hominis bacterium protected against DSS-induced colitis. These data reveal the immunomodulatory properties of R. hominis, suggesting a potential therapeutic benefit of R. hominis in the treatment of UC.

Inflammatory Bowel Disease (IBD)

In addition to its impact on UC, R. hominis has been studied in the broader context of IBD. Notably, the administration of R. hominis in germ-free rats led to an increase in intestinal melatonin levels. Melatonin plays a critical role in regulating gut motility and immune responses. The study revealed that the metabolites of R. hominis, including propionate and butyrate, promote the synthesis of intestinal melatonin by increasing serotonin (5-HT) levels and activating Aanat transcription via p-CREB signaling. These findings present a compelling case for the therapeutic application of R. hominis in gut diseases, particularly by targeting melatonin production and improving intestinal homeostasis.

Fig. 1 Potential mechanisms of R. hominis in intestinal melatonin synthesis.¹

Immunomodulation and Gut Health

The ability of R. hominis to regulate the immune system has broad implications beyond gastrointestinal diseases. Research involving murine models has shown that R. hominis can induce specific gene expression patterns, influencing both bacterial and host cell responses. In bacterial cells, genes related to motility, metabolism, and chemotaxis were upregulated upon colonization of the host gut. Meanwhile, in host cells, genes related to TLR signaling and T-cell biology were activated, strengthening the intestinal barrier and promoting immune tolerance.

What Services Can We Provide for R. hominis?

Creative Biolabs offers a comprehensive range of services to support the discovery and development of R. hominis as a next-generation probiotic. By leveraging advanced microbial technologies, we facilitate the isolation, characterization, and analysis of R. hominis strains for therapeutic purposes, focusing on gut health and inflammation-related diseases. Researchers can benefit from specialized services such as microbial identification, purification, SCFA production analysis, and in vitro immune modulation tests. Additionally, biological safety tests and small-scale production ensure the high-quality development of R. hominis strains. With tailor-made solutions, we provide flexibility in research design, assisting in strain selection, metabolic analysis, and preclinical testing to guarantee the efficacy and safety of R. hominis products for research.

Advanced Technology Platforms for R. hominis

Creative Biolabs employs cutting-edge technological platforms to support research and development of R. hominis as a next-generation probiotic. These platforms enable precise identification, analysis, and testing of the probiotic properties of R. hominis strains.

• High-Throughput Screening: We offer high-throughput screening capabilities to rapidly identify R. hominis strains with desirable probiotic characteristics. This includes screening for high butyrate production and immune-modulating effects.
• Genomic and Metagenomic Sequencing: Using whole genome sequencing (WGS), 16S rRNA gene sequencing, and other genomic sequencing technologies, we provide comprehensive insights into the genetic makeup of R. hominis. This facilitates the identification of genes associated with probiotic activity, such as SCFA production and immune modulation.
• In Vitro and In Vivo Testing: In vitro and in vivo platforms are available to evaluate the potential of R. hominis in disease models. For example, in vitro tests of immune system modulation allow researchers to assess how R. hominis affects immune cells, while in vivo animal models, such as those for colitis, are used to validate the bacterium's efficacy in reducing inflammation.

R. hominis Related Products at Creative Biolabs

• Strain Products

We supply a variety of R. hominis strains of different preservation numbers as below. If you need other strains, please contact us.

• Customized strain culture supernatant. (e.g., for animal research)
• Customized strain lyophilized powder containing certain CFU. (e.g., for animal research)

Creative Biolabs' team is diverse, knowledgeable, and agile, with a solid leadership universally recognized in the world of LBP. With our effective tools, extensive knowledge, unwavering support, assuring our partner's projects go forward successfully. If you are interested in our R. hominis related products and services, please feel free to contact us for more.

Introduction of R. hominis

Roseburia hominis is a flagellated, anaerobic bacterium within the Lachnospiraceae family of the Firmicutes, first isolated from human fecal samples in the United Kingdom. This species plays a significant role in maintaining gut health by producing butyrate, a short-chain fatty acid (SCFA) essential for maintaining intestinal integrity and regulating inflammatory responses. As a slightly curved, rod-shaped, motile bacterium, R. hominis exhibits Gram-variable characteristics, with cell sizes ranging from 0.5-1.5 to 5.0 µm in length. The R. hominis has become the cornerstone of research in probiotic development, particularly in its role as a next-generation probiotic (NGP).

The depletion of R. hominis has been closely linked to dysbiosis in various gastrointestinal disorders, such as ulcerative colitis (UC) and inflammatory bowel disease (IBD). Numerous studies have demonstrated that individuals suffering from these conditions often present with lower levels of butyrate-producing bacteria, including R. hominis and Faecalibacterium prausnitzii. Given its beneficial role in butyrate production and its influence on host immunity, R. hominis has garnered attention for its therapeutic potential in gut health and its prospective role in next-generation probiotics.

FAQs

Resources

Reference

1. Song, Lijin, et al. "Roseburia hominis increases intestinal melatonin level by activating p-CREB-AANAT pathway." Nutrients 14.1 (2021): 117. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.